FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	Responses)																		
1. Name and Address of Reporting Person + HUNT RONALD					2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, FITZWILLIAM COURT, FL. 1, LEESON CLOSE					3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022								ve title below)			pecify below)			
DUBLIN 2, L2				4. I	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ I	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	<u> </u>	(State)	(Zip)				Т	able I - I	Non-	Derivati	ve Securi	ties A	cquired,	Disposed	l of, or Ben	eficiall	ly Owned		
(Instr. 3) Date (Month/Day/Year) a			Exect	2A. Deemed Execution Date, if any (Month/Day/Year)			(Instr. 8)		on 4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)					ed Following		6. Ownershi Form: Direct (D	7. Nature p Indirect Beneficial	al	
			(Code	V	Amount (A) or (D) Price		-,			or Indirection (I) (Instr. 4)		(Instr. 4)				
Ordinary S	Shares		06/23/2022	06/2	23/2022	2		M		36,798	A	(1)	42,501				D		
Ordinary Shares												1,071,)71,688 I		I	By New Leaf Ventures III, L.P. (2)			
Ordinary Shares												384,61	384,615			I	By New Leaf Biopharma Opportunities II, L.P. (3)		
Reminder: Re	eport on a se	parate line for e	each class of securiti	es ben	neficially	owi	ned o	directly or	Pe co	rsons w ntained	in this fo	orm a	re not r	equired	of informa to respon- ntrol numl	d unle	ess the	SEC 147	74 (9-02)
			Table I								of, or Be			ned					
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Date or Exercise Price of Perivative Security		Execution Da	te, if	4. Transaction Code		5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Tof I	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Security (Instr. 5) E	Deriv Secur Benet Owne Follor Repor Trans	erivative ecurities eneficially wned ollowing eported ransaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	V	(A)	(D)	Da Exc	te ercisable	Expiration Date	n Titi	le	Amount or Number of Shares		(Instr	. 4)	(Instr. 4)	
Restricted Share Units	\$ 0 (1)	06/23/202	22 06/23/202	22	М			36,798		(4)	<u>(4)</u>		rdinary Shares	36,798	\$ 0		0	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
HUNT RONALD C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE DUBLIN 2, L2	X						

Signatures

/s/ Ronald M. Hunt	06/24/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.
 - These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting,
- (2) investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any.
 - These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-III may be deemed to have sole voting, investment and
- (3) dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any.
- (4) On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.